Company patents
GENFIT
GENFIT's patent strategy, while heavily concentrated in core pharma categories like Pharmaceutical Preparations (80.4% of portfolio) and Therapeutic Activity (Pharma) (67.4%), shows a surprising, albeit short-lived, surge in Healthcare Informatics, which grew by 200.0% in 2024 before declining significantly. The company appears to be shifting away from several computing-related categories, with Computer Hardware Architecture, Bioinformatics, Image Processing, and Machine Learning & AI all seeing a 100.0% decline in 2025 and no patents so far in 2026.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
46 US filings (since 2023) · 12 categories · 3 themes
Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.
Methods and compositions for identifying, quantifying, or characterizing specific biological molecules (e.g., nucleic acids, proteins, metabolites, antibodies) or microbial species, often for diagnostic, prognostic, or quality control applications.
Delivery systems specifically engineered to administer advanced drug formulations (e.g., microparticles, biologics, extended-release systems) to achieve precise targeting, controlled release kinetics, or enhanced therapeutic efficacy within the body.
Patents
Showing 1-10 of 79